Reproductive Endocrinology Practice Questions

Q: The Fern test is indicative of which physiological change?

Presence of Sodium Chloride (NaCl) under estrogenic effect. **Explanation:** The **Fern test** (arborization) is a classic clinical test used to assess the estrogenic status of a patient. 1. **Why Option B is Correct:** Under the influence of **estrogen** (predominantly during the follicular phase), cervical mucus becomes thin, watery, and alkaline. High levels of estrogen lead to an increased concentration of **Sodium Chloride (NaCl)** in the mucus. When this mucus is spread on a glass slide and allowed to air-dry, the crystallization of NaCl creates a characteristic "palm-leaf" or "fern-like" pattern under the microscope. 2. **Why Other Options are Incorrect:** * **Option A:** **Progesterone** has the opposite effect. It makes the mucus thick, cellular, and acidic, which inhibits crystallization. This is known as the "smear pattern" or "non-ferning" effect, typical of the luteal phase or pregnancy. * **Option C:** While LH and FSH regulate the cycle, the Fern test specifically measures the end-organ response (cervical mucus) to steroid hormones, not the gonadotropins themselves. * **Option D:** While the glands do secrete the mucus, the "Fern" pattern specifically refers to the chemical crystallization of salts, not the mere presence of secretion. **High-Yield NEET-PG Pearls:** * **Peak Ferning:** Occurs between days 12–16 of a normal menstrual cycle (pre-ovulatory estrogen peak). * **Disappearance of Ferning:** If ferning disappears after day 21, it indicates successful **ovulation** (due to progesterone production by the corpus luteum). * **Clinical Use:** Used to detect ovulation, assess estrogen deficiency, or confirm the **Premature Rupture of Membranes (PROM)**, as amniotic fluid also shows a positive fern test. * **Spinnbarkeit Effect:** Another estrogenic marker where cervical mucus can be stretched into a long thread (usually >8-10 cm) just before ovulation.

Q: In the given flowchart regarding the pathophysiology of polycystic ovarian syndrome, what does 'A' represent?

Oestrogen. ***Oestrogen*** - In PCOS pathophysiology, **peripheral aromatization** of androstenedione produces **estrone** (a form of estrogen), which creates a positive feedback loop with **LH hypersecretion**. - This **tonic estrogen stimulation** maintains elevated **LH levels** without the normal cyclical patterns, perpetuating the **vicious cycle** of androgen excess. *Inhibin - B* - **Inhibin-B** is produced by **granulosa cells** and primarily inhibits **FSH secretion**, not involved in the LH feedback loop shown in PCOS pathophysiology. - In PCOS, **inhibin-B levels** are typically **decreased** due to impaired follicular development, making it unsuitable for position 'A'. *Progesterone* - **Progesterone** is typically **deficient** in PCOS due to **anovulation** and lack of corpus luteum formation. - It would provide **negative feedback** on LH, which contradicts the **positive feedback loop** required at position 'A' in PCOS pathophysiology. *Androstenedione* - **Androstenedione** is the **precursor hormone** produced by theca cells under LH stimulation, not the feedback hormone to the hypothalamic-pituitary axis. - It serves as the **substrate** for estrogen production through **peripheral aromatization**, rather than the feedback mediator itself.

Q: What is the primary drug used in the treatment of hirsutism in Polycystic Ovarian Disease (PCOD)?

Spironolactone. **Explanation:** **Polycystic Ovarian Disease (PCOD/PCOS)** is characterized by hyperandrogenism, which clinically manifests as hirsutism. The management of hirsutism focuses on blocking androgen action at the hair follicle. **Why Spironolactone is correct:** Spironolactone is a potassium-sparing diuretic that acts as a potent **androgen receptor antagonist**. It also inhibits **5-alpha reductase** (the enzyme converting testosterone to the more potent dihydrotestosterone) and interferes with ovarian steroidogenesis. Due to this dual mechanism, it is the most commonly used anti-androgen for treating hirsutism in PCOS when Combined Oral Contraceptives (COCs) alone are insufficient. **Why other options are incorrect:** * **Menopausal Gonadotropin (hMG) & hCG:** These are used for **ovulation induction** in infertile patients with PCOS. They stimulate the ovaries and can actually increase androgen production, potentially worsening hirsutism. * **GnRH:** While GnRH analogs can suppress the pituitary-ovarian axis to reduce androgens, they are not the "primary" treatment due to side effects (bone loss, vasomotor symptoms) and high cost. **High-Yield Clinical Pearls for NEET-PG:** * **First-line treatment:** Lifestyle modification and **COCs** are usually the first-line medical therapy for PCOS. Spironolactone is added if there is no improvement after 6 months. * **Teratogenicity:** Spironolactone can cause feminization of a male fetus; therefore, it **must** be used with effective contraception. * **Other Anti-androgens:** Cyproterone acetate, Finasteride, and Flutamide are also used, but Spironolactone remains a classic exam favorite. * **Eflornithine:** A topical cream used specifically for facial hirsutism.

Q: What is the most common cause of abortion in the first trimester?

Embryonic defect. **Explanation:** **Correct Answer: C. Embryonic defect** The most common cause of spontaneous abortion in the first trimester is an **embryonic defect**, specifically **chromosomal abnormalities**. Approximately 50–60% of all first-trimester miscarriages are attributed to genetic errors. Among these, **Autosomal Trisomy** is the most frequent (Trisomy 16 being the most common specific trisomy), followed by Monosomy X (Turner Syndrome) and Polyploidy. These defects usually result from errors in gametogenesis or fertilization rather than maternal factors, leading to non-viable embryos that the body naturally expels. **Why other options are incorrect:** * **A. Placental defect:** While placental issues (like circumvallate placenta or retroplacental hemorrhage) can cause pregnancy loss, they are more frequently associated with second-trimester losses or late pregnancy complications rather than early first-trimester abortions. * **B. Uterine defect:** Anatomical issues (e.g., septate uterus, submucosal fibroids, or cervical incompetence) are significant causes of **recurrent** pregnancy loss or mid-trimester abortions, but they are statistically less common than chromosomal defects in the first trimester. * **D. Ovarian defect:** Luteal phase deficiency (inadequate progesterone production by the corpus luteum) can lead to miscarriage, but it accounts for a very small percentage of cases compared to embryonic factors. **High-Yield NEET-PG Pearls:** * **Most common chromosomal abnormality:** Autosomal Trisomy (50%). * **Most common specific Trisomy:** Trisomy 16 (never seen in live births). * **Most common single chromosomal anomaly:** Monosomy X (45, X). * **Timing:** 80% of spontaneous abortions occur within the first 12 weeks of pregnancy.

Q: A patient diagnosed with hypogonadism has normal FSH and estradiol levels. According to the WHO classification of disorders of ovulation, to which type does this patient belong?

Type II. ### Explanation The WHO classification of ovulatory disorders is a high-yield topic for NEET-PG, categorizing patients based on the hormonal axis (Hypothalamus-Pituitary-Ovary). **1. Why Type II is Correct:** **WHO Type II (Eu-gonadotropic Eu-estrogenic)** is characterized by **normal FSH and normal Estradiol** levels. This is the most common category of ovulatory dysfunction (approx. 85%). The classic clinical example is **Polycystic Ovary Syndrome (PCOS)**. Although the hormones are within the "normal" range, the cyclical rhythm is disrupted, leading to oligo-ovulation or anovulation. **2. Why Other Options are Incorrect:** * **Type I (Hypogonadotropic Hypogonadism):** Characterized by **Low FSH and Low Estradiol**. This results from hypothalamic or pituitary failure (e.g., Kallmann syndrome, excessive exercise, or stress). * **Type III (Hypergonadotropic Hypogonadism):** Characterized by **High FSH and Low Estradiol**. This indicates **Premature Ovarian Failure (POF)** or Primary Ovarian Insufficiency; the pituitary is overworking to stimulate non-responsive ovaries. * **Type IV (Hyperprolactinemic Anovulation):** Though sometimes categorized separately, it involves elevated prolactin levels which inhibit GnRH pulsatility, leading to anovulation despite normal ovarian reserve. **3. Clinical Pearls for NEET-PG:** * **Most Common Type:** WHO Type II (PCOS). * **Treatment of Choice (Type I):** Pulsatile GnRH or Gonadotropins (hMG/FSH). * **Treatment of Choice (Type II):** Lifestyle modification followed by Letrozole (first-line) or Clomiphene Citrate. * **Progestogen Challenge:** Patients with Type II will have a **positive** withdrawal bleed (due to presence of estrogen), whereas Type I and Type III will usually be negative.

Q: All of the following are raised in PCOS except?

E2:E1 ratio. In Polycystic Ovary Syndrome (PCOS), the hormonal and metabolic profile is characterized by hyperandrogenism and insulin resistance. **Explanation of the Correct Answer:** * **A. E2:E1 ratio:** In PCOS, the ratio of **Estradiol (E2) to Estrone (E1) is decreased**, not raised. While E2 is the primary estrogen produced by the ovaries, PCOS involves significant peripheral aromatization of androstenedione into Estrone (E1) within adipose tissue. Consequently, **E1 levels become higher than E2**, leading to a reversal of the normal ratio. **Explanation of Incorrect Options:** * **B. LH:FSH ratio:** Raised. High-frequency GnRH pulses favor LH secretion over FSH. A ratio of **>2:1 or 3:1** is a classic (though not diagnostic) finding. * **C. LDL:HDL ratio:** Raised. Insulin resistance and hyperandrogenism lead to dyslipidemia, specifically increasing "bad" cholesterol (LDL) and decreasing "good" cholesterol (HDL). * **D. Fasting serum insulin:** Raised. Peripheral insulin resistance is a hallmark of PCOS, leading to compensatory hyperinsulinemia, which further stimulates ovarian androgen production. **High-Yield Clinical Pearls for NEET-PG:** * **Hyperestrogenism in PCOS:** It is a state of "chronic tonic estrogen" (mostly E1) without the progesterone surge, leading to an increased risk of **Endometrial Hyperplasia/Carcinoma**. * **SHBG:** Sex Hormone Binding Globulin is **decreased** in PCOS due to high insulin, leading to increased levels of **Free Testosterone**. * **Gold Standard for Insulin Resistance:** Hyperinsulinemic-euglycemic clamp (though rarely used clinically). * **AMH:** Anti-Müllerian Hormone levels are typically **raised** due to the high number of pre-antral follicles.

Q: Which of the following is NOT a typical symptom or sign of Polycystic Ovarian Disease (PCOD)?

Weight loss. **Explanation:** **Polycystic Ovarian Disease (PCOD/PCOS)** is a complex endocrine disorder characterized by insulin resistance, hyperandrogenism, and chronic anovulation. **Why Weight Loss is the Correct Answer:** Weight loss is **not** a feature of PCOD; instead, **obesity** (specifically central/android obesity) is a hallmark sign, seen in approximately 50-60% of patients. Obesity exacerbates the condition because adipose tissue decreases Sex Hormone Binding Globulin (SHBG) and increases peripheral conversion of androgens to estrogens, further disrupting the hypothalamic-pituitary-ovarian axis. **Analysis of Incorrect Options:** * **Alopecia:** High levels of circulating free androgens (testosterone) lead to "male-pattern" hair loss (androgenetic alopecia) and hirsutism. * **Theca Cell Hyperplasia:** In PCOD, elevated Luteinizing Hormone (LH) levels cause hyperplasia of the ovarian theca cells. These cells are responsible for the overproduction of androgens (androstenedione and testosterone). * **Hyperandrogenism:** This is a core diagnostic criterion (Rotterdam Criteria). It manifests clinically as acne, hirsutism, and biochemically as elevated serum testosterone levels. **High-Yield Clinical Pearls for NEET-PG:** * **Rotterdam Criteria (2 out of 3):** 1. Oligo/Anovulation, 2. Clinical/Biochemical Hyperandrogenism, 3. Polycystic ovaries on Ultrasound ("String of pearls" appearance). * **LH:FSH Ratio:** Classically elevated to **>2:1 or 3:1**. * **Insulin Resistance:** Leads to **Acanthosis Nigricans** (velvety hyperpigmentation in skin folds). * **First-line Management:** Weight loss and lifestyle modification. For infertility, **Letrozole** is now the drug of choice (DOC), surpassing Clomiphene Citrate.

Q: All of the following statements about Androgen Insensitivity Syndrome are true except?

Pubic hair are abundant. **Explanation:** **Androgen Insensitivity Syndrome (AIS)**, formerly known as Testicular Feminization Syndrome, is an X-linked recessive condition where there is a functional defect in the androgen receptors. **Why Option B is the correct answer (The False Statement):** In AIS, although the body produces high levels of testosterone, the peripheral tissues cannot respond to it due to receptor resistance. Since the development of **pubic and axillary hair** is dependent on androgen action, these patients typically have **absent or very sparse** pubic and axillary hair. Therefore, the statement that pubic hair is "abundant" is incorrect. **Analysis of Incorrect Options:** * **Option A (XY Genotype):** True. These individuals are genetically male (46, XY). * **Option C (Blind Vagina):** True. Due to the presence of the Y chromosome, the SRY gene leads to the development of testes which secrete **Müllerian Inhibiting Substance (MIS)**. MIS causes regression of the Müllerian ducts (uterus, fallopian tubes, and upper 1/3rd of the vagina). The lower 2/3rd of the vagina (derived from the urogenital sinus) develops but ends blindly. * **Option D (Ovaries are absent):** True. These patients have undescended testes (often located in the labia majora or inguinal canal) rather than ovaries. **High-Yield Clinical Pearls for NEET-PG:** * **Phenotype:** Phenotypically female with well-developed breasts (due to peripheral conversion of testosterone to estrogen). * **Primary Amenorrhea:** AIS is a leading cause of primary amenorrhea with breast development. * **Management:** Gonadectomy is performed **after puberty** (to allow natural breast development) to prevent the risk of gonadoblastoma/dysgerminoma. * **Differential Diagnosis:** Differentiate from **Müllerian Agenesis (MRKH Syndrome)** where the genotype is 46, XX, ovaries are present, and pubic hair is normal.

Question 1

The Fern test is indicative of which physiological change?

Accepted Answer

Presence of Sodium Chloride (NaCl) under estrogenic effect

Answer

Presence of Sodium Chloride (NaCl) under progesterone effect

Answer

Luteinizing Hormone (LH)/Follicle-Stimulating Hormone (FSH) levels

Answer

Mucus secretion by glands

Question 2

A 17-year-old girl presents with primary amenorrhea. On examination, there is absent breast development, but the vagina is normal. Ultrasound reveals a hypoplastic uterus, and bilateral ovaries are not visualized. What is the most likely diagnosis?

Accepted Answer

Turner syndrome

Answer

Swyer syndrome

Answer

Müllerian agenesis

Answer

Androgen insensitivity syndrome

Question 3

In the given flowchart regarding the pathophysiology of polycystic ovarian syndrome, what does 'A' represent?

Accepted Answer

Oestrogen

Answer

Inhibin - B

Answer

Progesterone

Answer

Androstenedione

Question 4

What is the primary drug used in the treatment of hirsutism in Polycystic Ovarian Disease (PCOD)?

Accepted Answer

Spironolactone

Answer

Menopausal Gonadotropin

Answer

Gonadotropin-Releasing Hormone (GnRH)

Answer

Human Chorionic Gonadotropin (hCG)

Question 5

What is the most common cause of abortion in the first trimester?

Accepted Answer

Embryonic defect

Answer

Placental defect

Answer

Uterine defect

Answer

Ovarian defect

Question 6

A female patient presents with primary amenorrhea. She has a negative progesterone challenge test but a positive response to combined estrogen and progesterone administration. What is the most likely diagnosis?

Accepted Answer

Prolactinoma

Answer

Mullerian agenesis

Answer

Polycystic ovary disease (PCOD)

Answer

Asherman syndrome

Question 7

A patient diagnosed with hypogonadism has normal FSH and estradiol levels. According to the WHO classification of disorders of ovulation, to which type does this patient belong?

Accepted Answer

Type II

Answer

Type I

Answer

Type III

Answer

Type IV

Question 8

All of the following are raised in PCOS except?

Accepted Answer

E2:E1 ratio

Answer

LH:FSH ratio

Answer

LDL:HDL ratio

Answer

Fasting serum insulin

Question 9

Which of the following is NOT a typical symptom or sign of Polycystic Ovarian Disease (PCOD)?

Accepted Answer

Weight loss

Answer

Alopecia

Answer

Theca cell hyperplasia

Answer

Hyperandrogenism

Question 10

All of the following statements about Androgen Insensitivity Syndrome are true except?

Accepted Answer

Pubic hair are abundant

Answer

Patients have an XY genotype

Answer

A blind vagina may be present

Answer

Ovaries are absent

Reproductive Endocrinology — MCQs

Reproductive Endocrinology — MCQs

On this page

Practice by Chapter

Want unlimited practice?